New securities class action lawsuits in the first half of 2026 were filed at a pace that projects to a year-end total number of filings ahead of both 2025’s full-year total and long-term year-end averages.
Continue Reading Securities Lawsuit Filings Up in Year’s First Half
In the following guest post, Justin Bove, Chief Revenue Officer and Fiduciary Lead at Encore Fiduciary, reviews and analyses the ERISA fiduciary class action lawsuits filed in 2025. A version of this article previously was published on Encore’s Fid Guru Blog (here). My thanks to Justin for allowing me to publish his article on this site. Here is Justin’s article.
Continue Reading Guest Post: The State of ERISA Fiduciary Litigation in 2025
The directors’ and officers’ liability environment is always changing, but 2025 was a particularly eventful year, with important consequences for the D&O insurance marketplace. The past year’s many developments also have significant implications for what may lie ahead in 2026 – and possibly for years to come. I have set out below the Top Ten D&O Stories of 2025, with a focus on future implications. Please note that on Thursday, January 15, 2026 at 11:00 am EST, my colleagues Marissa Streckfus, Chris Bertola, and I will be conducting a free, hour-long webinar in which we will discuss The Top Ten D&O Stories of 2025. Registration for the webinar can be found here. Please join us for the webinar.
Continue Reading The Top Ten D&O Stories of 2025
After two consecutive years in which the annual number of federal court securities class action lawsuit filings increased, the number of federal court securities class action lawsuit filings decreased slightly in 2025 compared to 2024, to the lowest level since 2022. The number of federal court securities class action suit filings during past year reflected the impact of several ongoing securities lawsuit filings trends, such as the new lawsuit filings relating to artificial intelligence (AI) and cryptocurrencies. The slight decline in the annual number of filings reflects the diminishing impact of certain long-term trends that waned during the year, as discussed below.
Continue Reading Federal Court Securities Suit Filings Declined Slightly in 2025
It is frequently the case that securities class action lawsuits are accompanied by a parallel shareholder derivative lawsuit involving substantially similar allegations. But what happens to the derivative lawsuits when the related securities class action lawsuit is settled? An August 2025 study from Cornerstone Research analyzes the settlements of these parallel derivative lawsuits during the period 2019 through 2024. The Cornerstone Research report can be found here.
Continue Reading Settlement of Parallel Derivative Actions
In a recent study about securities class action lawsuit filings in the first six months of 2025, NERA reports that first half filings represented a tale of two quarters, with the first quarter filings representing the highest quarterly number in five years, and the second quarter filings represented the lowest quarterly filing number in five years. The report, which is entitled “Recent Trends in Securities Class Action Litigation: H1 2025 Update,” and which can be found here, includes a number of other interesting observations, as discussed below.
Continue Reading NERA Reports on 1H25 Federal Court Securities Class Action Lawsuit Filings
New securities class action lawsuits in the first half of 2025 were filed at a pace that projects to a year-end total number of filings level with 2024’s full-year total.
Continue Reading First Half Securities Suit Filings on Pace to Match Last Year’s Filings Total
Long-time observers of securities class action litigation filing patterns know well that life sciences companies are frequent targets of securities suit, reflecting a litigation frequency pattern that has been well-established for years. While in more recent years the overall number of securities suits filed against life sciences has shown a marginal decline, in 2024, the number of securities suits filed against life sciences companies increased to the highest level in several years, according to the latest annual report from the Sidley law firm. A copy of the law firm’s recent memo, entitled “Securities Class Actions in the Life Sciences Sector: 2024 Annual Survey” can be found here. A two-page summary of the report can be found here.
Continue Reading A Detailed Look at the 2024 Securities Litigation Against Life Sciences Companies
According to the latest annual report from ISS Securities Class Action Services, there were four court-approved securities class action settlements in 2024 large enough to make the firm’s list of the Top 100 U.S. Securities Class Action settlements. These settlements took place in a year in which there were 136 court-approved monetary securities class action lawsuit settlements totaling over $4.7 billion. The details of the 2024 court approved settlements, including with respect to the four largest during the year, can be found in the ISS Securities Class Action Services report entitled “The Top 100 U.S. Class Action Settlements of All-Time” (as of December 31, 2024), here.
Continue Reading ISS Releases Top 100 Securities Suit Settlements List
The filing of Opioid-related securities litigation is not a new development; indeed, more than six years ago, I published a post in which I noted the outbreak at the time of a number of opioid-related securities suits against opioid drug companies. Now, in the latest opioid-related securities suits to be filed, and in the wake of the U.S. Department of Justice’s filing of a False Claims Act complaint against the company, a plaintiff shareholder has filed an opioid-related securities class action lawsuit against Walgreens Boots Alliance. A copy of the January 30, 2025, complaint can be found here.
Continue Reading Walgreens Boots Alliance Hit with Opioid-Related Securities Suit